#United States #Marlborough #Boston Scientific #Neuromodulation #Nalu Medical

Boston Scientific to Acquire Nalu Medical

Boston Scientific Corporation, a leader in medical technology, recently made headlines by announcing its definitive agreement to acquire Nalu Medical, Inc., a medical technology company focused on innovative solutions for chronic pain. This strategic acquisition aims to enhance Boston Scientific's neuromodulation offerings and expand its capabilities in treating patients suffering from chronic pain.

Details of the Acquisition

The transaction is set at an upfront payment of approximately $533 million, covering the remaining equity of Nalu Medical not currently owned by Boston Scientific. This acquisition builds upon Boston Scientific’s history as a strategic investor in Nalu Medical, having supported the firm since 2017.

Nalu Medical is known for its groundbreaking Nalu Neurostimulation System, which is designed to provide targeted relief for patients dealing with severe chronic pain, particularly from peripheral nerve origins. This system utilizes peripheral nerve stimulation (PNS) technology, delivering mild electrical impulses to manage pain signals before they reach the brain. Notably, the system boasts a compact, battery-free implantable pulse generator that is wirelessly powered by a small external therapy disc and can be controlled through a smartphone app.

Clinical Evidence Supporting Nalu's Technology

Nalu Medical gained U.S. FDA 510(k) clearance for its neurostimulation system in 2019. Clinical studies, including the COMFORT and COMFORT 2 trials, have produced promising results, demonstrating significant pain relief in patients utilizing the Nalu system. In the COMFORT trial, 87% of participants reported over a 50% reduction in pain after 12 months. Similarly, in the COMFORT 2 trial, 79% experienced an average pain relief of 64% at six months. Real-world data corroborates these findings, with 94% of over 2,000 patients reporting clinically significant improvements in managing peripheral nerve pain conditions.

A New Frontier in Pain Management

Jim Cassidy, President of Neuromodulation at Boston Scientific, expressed enthusiasm about the acquisition, stating, "Peripheral nerve stimulation is an exciting field with significant unmet patient needs. Adding Nalu Medical's advanced technology complements our existing therapies, allowing for the delivery of sophisticated pain relief options to a wider range of patients."

With the acquisition expected to finalize in the first half of 2026, Boston Scientific anticipates Nalu will generate over $60 million in sales by 2025, alongside offering progressive growth exceeding 25% in 2026. Despite initial dilutive effects on adjusted earnings per share (EPS), the long-term financial outlook remains positive as benefits from this acquisition are projected to outweigh costs in subsequent years.

Conclusion

Boston Scientific's acquisition of Nalu Medical seeks to cement its position as a frontrunner in the medical technology sphere, specifically in the neuromodulation market. The emphasis on innovative pain management solutions aligns with Boston Scientific’s mission to transform lives through technologically advanced medical devices. As the company moves forward, advancements in chronic pain therapies through this acquisition could herald a new era for patients struggling with chronic pain conditions.

For more information on Boston Scientific and to keep up with their latest innovations, visit their website at Boston Scientific.